Nebenwirkungen · Velphoro
Velphoro 500 mg chewable tablets · Abschnitt 4.8 · PDF-Seite 5
HOS-128616 · Präparat HOS-096593
In these clinical trials, approximately 43% of the patients experienced at least one adverse reaction during Velphoro treatment, and 0.36% of the adverse reactions were reported as serious. The majority of the adverse reactions reported from trials were gastrointestinal disorders, with the most frequently reported adverse reactions being diarrhoea and discoloured faeces (very common). The vast majority of these gastrointestinal disorders occurred early during treatment and abated with time with continued dosing. No dose-dependent trends were observed in the adverse reaction profile of Velphoro.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-24T02:00:00Z · SHA-256 1e5416d301655970abd63bd7dd9bc2b3e6c52e5764330496810361230bfa8aa9 · Passage 42b4fd29980947e7fde4e08f309edb672bf3b42be3ebc95d5a53ac540119ee87 · Zeichen 231–832 im Abschnitt